Premium
Attenuating Smac mimetic compound 3‐induced NF‐κB activation by luteolin leads to synergistic cytotoxicity in cancer cells
Author(s) -
Bai Lang,
Chen Wenjie,
Wang Xia,
Ju Wei,
Xu Shanling,
Lin Yong
Publication year - 2009
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.22346
Subject(s) - luteolin , apoptosis , autocrine signalling , tumor necrosis factor alpha , cancer cell , cancer research , nf κb , cancer , pharmacology , cytotoxic t cell , cytotoxicity , biology , cell culture , biochemistry , immunology , flavonoid , in vitro , genetics , antioxidant
Smac mimetics are potential anticancer therapeutics selectively killing cancer cells through autocrine tumor necrosis factor (TNF)‐mediated apoptosis pathway. Our recent study reveal that the Smac mimetic compound 3 (SMC3)‐activated NF‐κB protects cancer cells against apoptosis, thus blunting SMC3's anticancer activity. Based on our previous observations that the nutrient flavonoid luteolin potently blocks TNF‐induced NF‐κB activation in cancer cells, we investigated if the combination of SMC3 and luteolin would achieve a synergistic anticancer activity. The results show that luteolin had no effect on autocrine TNF but it effectively blocked SMC3‐induced nuclear factor kappa B (NF‐κB) activation and expression of anti‐apoptotic NF‐κB targets. When SMC3 and luteolin were combined in treating cancer cells derived from lung and liver tumors, the activation of TNF‐dependent apoptosis was markedly sensitized and a synergistic cytotoxic effect was achieved. In addition, the SMC3 and luteolin co‐treatment had marginal effect on immortalized normal human bronchial epithelial cells. The results suggest that combination of SMC3 and luteolin is an effective approach for improving the anticancer value of SMC3, which has implications in cancer prevention and therapy. J. Cell. Biochem. 108: 1125–1131, 2009. © 2009 Wiley‐Liss, Inc.